Global Bladder Cancer Trial Trends Reveal Immunotherapy Surge and Shortened Trial Cycles

Bladder cancer (BCa) ranks as the ninth most common malignancy worldwide, carrying high recurrence rates, treatment resistance, and variable outcomes. Despite meaningful therapeutic progress in recent years, a comprehensive view of global clinical trial trends had been lacking—until now. Researchers from Nanchang University conducted a systematic analysis of 2,899 BCa trials registered in the INFORMA database, which aggregates data from ClinicalTrials.gov, WHO ICTRP, EudraCT, PMDA, ChiCTR, and other international registries, as of April 25, 2025.

The data reveal a sharp rise in BCa trial activity starting around 2014, with a peak and subsequent stabilization after 2018. The United States dominates with 1,521 trials, followed by European and East Asian nations. Phase I/II trials constitute 86% of all studies, reflecting an innovation-heavy pipeline. The overall completion rate stands at 51%, but a concerning 18% termination rate—attributed to poor enrollment, business decisions, and early efficacy or safety signals—underscores the challenges of trial execution in precision oncology.

Immunotherapy overwhelmingly leads the mechanistic landscape. Immuno-oncology accounts for 1,058 trials, immune checkpoint inhibition for 725, and PD-1 antagonism specifically for 407. Traditional cytotoxic chemotherapy (gemcitabine, cisplatin) remains foundational, collectively represented through DNA synthesis and crosslinking inhibition categories with over 800 trials. Targeted therapy is growing but still underrepresented: anti-angiogenesis targeting reaches only 183 trials or fewer. Antibody-drug conjugates such as disitamab vedotin and enfortumab vedotin—the latter now a first-line standard in combination with pembrolizumab based on the EV-302 trial—are rapidly ascending. FGFR3 and HER2 represent key emerging molecular targets aligned with precision medicine.

One of the most striking findings is the dramatic compression of trial timelines. Average development cycles fell from 6–9 years in the 1990s to 5–6 years post-2000, and further to just 3–4 years after 2018. This acceleration reflects both the maturation of immunotherapy platforms and expedited regulatory pathways. Academic medical centers are the leading sponsors, followed by large and small pharmaceutical companies, with government funding comprising only a minority—highlighting the growing role of interdisciplinary academic-industry collaboration.

Key gaps identified include: a heavy research focus on stage III–IV and second-to-fourth-line treatment settings (73% and 74% of trials, respectively), leaving early-stage disease relatively understudied; geographic imbalance favoring North America, Europe, and East Asia while underrepresenting other regions; and relatively limited pharmacokinetic/pharmacodynamic endpoint assessment compared to efficacy and safety endpoints. The authors call for optimized patient recruitment strategies, stronger early efficacy prediction tools, and expanded global research collaboration to ensure treatment advances are broadly applicable.